Key facts
- This page summarizes Thomas Andrew Rowland's Form 4 filing for ANI PHARMACEUTICALS INC (ANIP).
- 1 reported transaction and 0 derivative rows are listed below.
- Accepted by SEC: 13 May 2026, 16:16.
Thomas Andrew Rowland - 12 May 2026 Form 4 Insider Report for ANI PHARMACEUTICALS INC (ANIP)
- Reporting relationship
- SVP, HEAD - ESTABLISHED BRANDS
- Issuer ticker
- ANIP
- Reported as of
- 12 May 2026
- Net transaction value
- -$36,357
- SEC form
- 4
- Accepted by SEC
- 13 May 2026, 16:16:49 UTC
- Prior SEC filing
- 13 Mar 2026
- Source filing
- View source filing
- Reporting owner signature
- /s/ Thomas Rowland, by attorney-in-fact Meredith W. Cook
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
Thomas Andrew Rowland filed Form 4 for ANI PHARMACEUTICALS INC (ANIP) on 13 May 2026.
Change
- Previous filing in this sequence was filed on 13 Mar 2026.
- Current net transaction value: -$36,357.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reporting Owners (1)
CIK 0001507496
Primary reporting owner
Rowland Thomas Andrew
- Relationship
- SVP, HEAD - ESTABLISHED BRANDS
- Address
- C/O ANI PHARMACEUTICALS, INC., 104 CARNEGIE CENTER, SUITE 300, PRINCETON
- Signature
- /s/ Thomas Rowland, by attorney-in-fact Meredith W. Cook
- Signature date
- 13 May 2026
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
ANIP
transaction
Common Stock
Sale
- Transaction value
- $36,357
- Shares
- -459
- Change %
- -1.2%
- Price
- $79.21
- Shares after
- 38,271
- Date
- 12 May 2026
- Ownership
- Direct
* marks a reported price that did not pass the local price check.